{"id":32934,"date":"2020-08-10T15:29:13","date_gmt":"2020-08-10T14:29:13","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=32934"},"modified":"2021-03-19T09:17:32","modified_gmt":"2021-03-19T09:17:32","slug":"patrice-garnier","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/","title":{"rendered":"Patrice Garnier"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n<h2>Dr. Patrice Garnier<\/h2>\n<h4>CEO at Amabiotics<\/h4>\n\t<p>Dr. Patrice Garnier is Chief Executive Officer for Amabiotics (<a href=\"http:\/\/www.amabiotics.com\/\">www.amabiotics.com<\/a>), a biopharmaceutical company that develops innovative diagnostics and microbiome- derived medicines to fight age-related diseases with a strong research focuses on gut-brain axis pathologies, metabolic disorders and oncology. The leading drug candidate, AMA-101, is a potential first-in- class therapy for Parkinson\u2019s disease.<\/p>\n<p>Dr. Garnier is an entrepreneur with 20 years of experience leading high-tech companies. Prior to joining Amabiotics in 2013, he founded and served for 9 years as CEO in a bioinformatics company that delivers genome to metabolome solutions for data analysis and management. He also co-founded IgenBio (www.igenbio. com) in 1993, a US based company which develops genome analysis products and services for the life science industry.<\/p>\n<p>Dr. Garnier holds an MSc in quantum physics from the \u00c9cole Normale Sup\u00e9rieure in Paris. He completed his PhD in nanotechnology in Professor Catherine Brechignac\u2019s group at the Laboratoire Aim\u00e9e Cotton, CNRS.<\/p>\n\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics_2.png\" alt=\"Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics_2\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics_2\" onerror=\"this.style.display='none'\" sizes=\"(max-width: 768px) 100vw, 100vw\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics_2.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics_2-201&#215;300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics_2-686&#215;1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics_2-768&#215;1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics_2-630&#215;940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics_2-420&#215;627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics_2-315&#215;470.png 315w&#8221;>\t\t\t\t\t\t\t\n<h3>\n\tTitle: From Microbiome Explorations to Effective Innovative Therapies in Parkinson Disease: a case study\n\t<\/h3>\n<ul>\n<li>From biochemical mechanisms to proof of concept: how to design a new microbiome-oriented strategy for Parkinson Disease<\/li>\n<li>Preclinical and clinical trials: the same road as pharmaceutical development?<\/li>\n<\/ul>\n\t<a href=\"\" target=\"_self\" role=\"button\" rel=\"noopener noreferrer\">\n\t\t\t\t\tPresentation not available\n\t<\/a>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener noreferrer\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.stellate-tx.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.stellate-tx.com\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener noreferrer\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/patrice-garnier-93426a1\/\" target=\"_blank\" rel=\"noopener noreferrer\">Visit Profile<\/a><\/p>\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Dr. Patrice Garnier CEO at Amabiotics Dr. Patrice Garnier is Chief Executive Officer for Amabiotics (www.amabiotics.com), a biopharmaceutical company that develops innovative diagnostics and microbiome- derived medicines to fight age-related diseases with a strong research focuses on gut-brain axis pathologies, metabolic disorders and oncology. The leading drug candidate, AMA-101, is a potential first-in- class therapy&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32935,"parent":32856,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-32934","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Patrice Garnier &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Dr. Patrice Garnier is Chief Executive Officer for Amabiotics, a biopharmaceutical company that develops innovative diagnostics and microbiome- derived medicines\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Patrice Garnier &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Dr. Patrice Garnier is Chief Executive Officer for Amabiotics, a biopharmaceutical company that develops innovative diagnostics and microbiome- derived medicines\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-19T09:17:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/\",\"name\":\"Patrice Garnier &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics.png\",\"datePublished\":\"2020-08-10T14:29:13+00:00\",\"dateModified\":\"2021-03-19T09:17:32+00:00\",\"description\":\"Dr. Patrice Garnier is Chief Executive Officer for Amabiotics, a biopharmaceutical company that develops innovative diagnostics and microbiome- derived medicines\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics.png\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gut-Brain Axis 2018 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Patrice Garnier\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Patrice Garnier &#8226; BioTech Pharma Summit","description":"Dr. Patrice Garnier is Chief Executive Officer for Amabiotics, a biopharmaceutical company that develops innovative diagnostics and microbiome- derived medicines","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/","og_locale":"en_US","og_type":"article","og_title":"Patrice Garnier &#8226; BioTech Pharma Summit","og_description":"Dr. Patrice Garnier is Chief Executive Officer for Amabiotics, a biopharmaceutical company that develops innovative diagnostics and microbiome- derived medicines","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-19T09:17:32+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/","name":"Patrice Garnier &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics.png","datePublished":"2020-08-10T14:29:13+00:00","dateModified":"2021-03-19T09:17:32+00:00","description":"Dr. Patrice Garnier is Chief Executive Officer for Amabiotics, a biopharmaceutical company that develops innovative diagnostics and microbiome- derived medicines","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Patrice_Garnier_BioTech_Pharma_Summit_Amabiotics.png","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/patrice-garnier\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Gut-Brain Axis 2018 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-2018-speakers\/"},{"@type":"ListItem","position":3,"name":"Patrice Garnier"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=32934"}],"version-history":[{"count":4,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32934\/revisions"}],"predecessor-version":[{"id":36132,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32934\/revisions\/36132"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/32856"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/32935"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=32934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}